Related Experiment Video

Updated: Aug 12, 2026

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Paraoxonase is reduced in patients with growth hormone deficiency: A novel risk factor for atherosclerosis

Fahri Bayram1, Gulden Baskol, Fatih Tanriverdi

  • 1Department of Endocrinology and Metabolism, Erciyes University Faculty of Medicine, Kayseri, Turkey.

Journal of Research in Medical Sciences : the Official Journal of Isfahan University of Medical Sciences
|October 15, 2013
PubMed

Insights

Growth hormone deficiency (GHD) is linked to higher oxidative stress, indicated by increased malondialdehyde (MDA) and lower antioxidant markers like paraoxonase1 (PON1) and thiol levels. This imbalance may increase cardiovascular risk in GHD patients.

Area of Science:

  • Biochemistry
  • Endocrinology
  • Cardiovascular Medicine

Background:

  • Growth hormone deficiency (GHD) is associated with increased cardiovascular mortality.
  • Oxidative stress plays a role in cardiovascular and cerebrovascular diseases.
  • Evaluating oxidant and antioxidant status in GHD is crucial for understanding associated risks.

Purpose of the Study:

  • To assess the oxidant and antioxidant status in patients with GHD.
  • To analyze serum paraoxonase1 (PON1) activity, malondialdehyde (MDA), and thiol levels in GHD patients.
  • To investigate the relationship between these markers and cardiovascular risk factors.

Main Methods:

  • A case-control study design was employed.
  • Thirty GHD patients were compared with 20 healthy controls.
  • Serum PON1 activity, MDA, and thiol levels were measured using enzymatic spectrophotometric methods.

Main Results:

  • GHD patients exhibited significantly higher serum MDA levels and lower PON1 activity, thiol, and HDL-cholesterol levels compared to controls.
  • Serum MDA levels negatively correlated with HDL-cholesterol.
  • PON1 activity positively correlated with thiol and HDL-cholesterol levels.

Conclusions:

  • GHD is characterized by an imbalance favoring oxidative stress over antioxidant defense.
  • This oxidative stress may contribute to the elevated atherogenic risk observed in GHD patients.
  • Further research is warranted to explore therapeutic strategies targeting oxidative stress in GHD.
Abstract

Keywords:
Growth hormone deficiencymalondialdehydeoxidative stressparaoxonase

Related Concept Videos

Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
3.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747